Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LP11 + OVA8 + CpG + LLP2A
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
LP11 + OVA8 + CpG + LLP2A is a programmable peptide nucleic acid (PNA)-based nanovaccine (PVN) designed for anticancer immune activation. The platform utilizes an 11-mer PNA scaffold (LP11) to facilitate the "one-pot" assembly of a PNA-modified ovalbumin antigenic peptide (OVA8/SIINFEKL), a CpG adjuvant, and a PNA-derivatized LLP2A ligand. The LLP2A ligand specifically targets the activated α4β1 integrin (VLA-4) expressed on both immune cells (such as dendritic cells) and melanoma cells. By co-delivering the antigen and the Toll-like receptor 9 (TLR9) agonist CpG, the nanovaccine enhances antigen presentation and elicits robust CD8+ T cell and natural killer (NK) cell responses, leading to significant tumor regression in syngeneic melanoma models.
- Other names
- PNA-based vaccine nanoplatformLP11-OVA8-CpG-LLP2ALP-11-OVA8-CpG-LLP2ALP 11-OVA8-CpG-LLP2A
02
Targets
TLR9 (Toll-like receptor 9)α4β1 (Integrin α4β1)
Beyond the preview
Go deeper on LP11 + OVA8 + CpG + LLP2A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LP11 + OVA8 + CpG + LLP2A.